Amgen, J&J Propose New Target Range For Aranesp, Procrit
Executive Summary
Just a year after FDA removed information related to a dosing target range for erythropoiesis-stimulating agents from product labeling, Amgen and Johnson & Johnson are proposing to re-establish a specific hemoglobin target range for the anemia therapies
You may also be interested in...
ASCO/ASH Guideline Preserves Higher ESA Dosing Options For Cancer Patients
Despite the emergence of safety concerns related to use of erythropoiesis-stimulating agents in recent years, the American Society of Hematology and the American Society of Clinical Oncology are essentially providing the same dosing recommendations in their latest guideline for treatment of chemotherapy-induced anemia as in the previous version from five years ago
Amgen Seeking ESA Dosing Algorithm As Scripts Continue To Fall In Oncology
Amgen is taking steps to construct dosing algorithms for its erythropoiesis-stimulating agents that may help mitigate problems stemming from heterogeneous patient response to the anemia therapies
ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says
Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says